Dihexa is an engineered small molecule, not a peptide, developed at Washington State University from angiotensin IV research to activate the HGF/c-Met growth-factor receptor system involved in synapse formation. Every finding for Dihexa itself is rodent data from its own developers’ papers; no human trial of Dihexa has ever been registered or published. A related but chemically distinct compound from the same lab, fosgonimeton, was the one actually carried into human Alzheimer’s trials, and the two should not be treated as the same drug.
Ask about Dihexa
Research snapshot
| Peptide category | Engineered small molecule (not a peptide), derived from angiotensin IV research |
| Primary research interest | Memory consolidation and synaptogenesis in rodent Alzheimer’s models, via HGF/c-Met receptor activation |
| Highest available evidence | Published animal (rodent) research, entirely from the compound’s own developers |
| Human research available | No: no registered or published human trial of Dihexa itself has ever been conducted |
| Development status | Never advanced to human trials; a related but chemically distinct compound, fosgonimeton, was carried into human Phase 2/3 Alzheimer’s trials instead |
| Regulatory status | Not approved for human use in any jurisdiction; no registered human trial |
Technical identity
| Primary name | Dihexa |
| Alternative names | N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; PNB-0408; “Dihexa peptide” (community name, though it is not a peptide) |
| Peptide sequence | Not applicable: Dihexa is a small synthetic molecule, not a peptide |
| Amino-acid length | Not applicable |
| Molecular formula | Not independently re-verified in this research pass |
| Molecular weight | Not independently re-verified in this research pass |
| CAS Registry Number | Not independently re-verified in this research pass |
| PubChem CID | Not independently re-verified in this research pass |
| UNII | Not established |
| DrugBank ID | Not established |
| Chemical modifications | Engineered analogue of angiotensin IV / Nle1-angiotensin IV, built for oral bioavailability and blood-brain-barrier penetration |
| Peptide class | Not a peptide: a designed small molecule from the brain renin-angiotensin system research program |
| Primary biological target | HGF (hepatocyte growth factor) / c-Met receptor system |
| Developer or originator | John Wright and Joseph Harding, Washington State University; licensed to M3 Biotechnology (later Athira Pharma) |
| Development status | Rodent-stage research only; the related compound fosgonimeton (from the same lab) is the one that reached human trials |
What it is
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic molecule developed at Washington State University by John Wright and Joseph Harding, derived from the brain renin-angiotensin system compound Nle1-angiotensin IV. It is not a peptide in the sense most entries on this site use the word; it is a designed, metabolically stabilised small molecule built to activate the hepatocyte growth factor (HGF)/c-Met receptor system, a growth-factor pathway involved in synapse formation. It has never been approved for human use anywhere, and it is not undergoing any registered human clinical trial.
The compound was licensed to M3 Biotechnology (later renamed Athira Pharma), a company the same researchers co-founded. Athira went on to develop a related but chemically distinct compound, fosgonimeton, through human Phase 2 and Phase 3 Alzheimer’s trials; those later-stage human trials were run on fosgonimeton, not on Dihexa itself, and the two should not be treated as interchangeable.
Potential benefits and research applications
Memory consolidation and retrieval in Alzheimer’s models, demonstrated only in rodents
Papers by Dihexa’s own developers report that it facilitates memory consolidation and retrieval in rodent models of Alzheimer’s disease, proposed to work through new synapse formation driven by HGF/c-Met activation.
Evidence: has been shown in rodent models by the compound’s own developers (Tier 3, published animal evidence, single research group); has not been established in any human trial, and none has been registered.
Oral bioavailability and blood-brain-barrier penetration, a pharmacology property rather than a clinical benefit
The same developer papers describe Dihexa as orally active and able to cross the blood-brain barrier in animal models, engineered specifically to fix the poor oral bioavailability of its parent compound, angiotensin IV.
Evidence: is a laboratory/animal pharmacology finding (Tier 3-4); has not been confirmed in any human pharmacokinetic study, because none exists.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Human research | Not applicable | No established or reliably sourced human dosing information was identified | Not applicable | Not applicable | No human trial of Dihexa has ever been conducted |
| Memory/synaptogenesis (rodent models) | Oral (rodent studies) | Engineered for high potency at oral doses well below typical peptide-drug quantities; no figure published that scales cleanly to a human milligram dose | Not consistently reported | Not consistently reported | Published animal research (developers’ own papers) |
| Cognitive support, general (community use) | Oral or subcutaneous | Commonly reported as 5 to 10 mg per dose | Once daily | Often cycled, weeks | Community / vendor reported: not derived from, or comparable to, anything published for this compound |
What has actually been tested
Every finding for Dihexa specifically comes from the same small group of review and mechanism papers by its own developers, describing rodent studies. Those papers report that Dihexa is orally active, crosses the blood-brain barrier, and facilitates memory consolidation and retrieval in animal models of Alzheimer’s disease by promoting the formation of new synaptic connections through HGF/c-Met activation.
No registered clinical trial of Dihexa itself was found on ClinicalTrials.gov. The compound has not, to the sources reviewed for this entry, been given to a human being in a published study.
What is not known
Whether Dihexa’s reported memory and synaptogenesis effects in rodents translate to a human being at any dose, by any route. No human trial exists.
Human pharmacokinetics, human safety, and human dosing at any level.
Whether Dihexa shares the safety and efficacy profile of fosgonimeton, the related compound its own developers carried into human trials instead. The two are chemically distinct molecules from the same research program, not the same drug under two names.
Frequently asked questions
What is Dihexa?
Dihexa is an engineered small molecule, not a peptide, developed from angiotensin IV research to activate the HGF/c-Met growth-factor receptor pathway. It has never been tested in a human being.
How does Dihexa work?
It is proposed to activate the HGF/c-Met receptor system, promoting new synapse formation, based entirely on rodent studies from its own developers.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified. No human trial of Dihexa has ever been conducted.
What dosage commonly circulates online?
Community material describes 5 to 10 milligrams orally or subcutaneously, once daily. This figure has no published animal or human dose-response study behind it that this entry could locate.
Has Dihexa been studied in humans?
No. No registered clinical trial of Dihexa appears on ClinicalTrials.gov, and no published human study was located for this entry.
Is Dihexa approved for use?
No. It is not approved for human use in any jurisdiction and has no registered human trial.
What routes of administration are reported?
Rodent studies describe oral administration. Community-reported human use describes oral or subcutaneous administration.
Is Dihexa the same as fosgonimeton?
No. Fosgonimeton is a related but chemically distinct compound from the same research program that was actually carried into human Phase 2 and Phase 3 Alzheimer’s trials. Human data on fosgonimeton does not establish anything about Dihexa itself.
What side effects have been reported?
No human safety or adverse-event data exists, because no human trial of Dihexa has been conducted.
What remains unknown about Dihexa?
Whether its rodent memory and synaptogenesis effects reproduce in a human being; its human pharmacokinetics, safety and dosing, none of which exist; and whether it behaves like fosgonimeton, the related compound that was actually tested in people.
Bottom line
Dihexa is an interesting piece of angiotensin-IV pharmacology with a genuinely misleading public profile: it is sold and discussed as a research peptide with cognitive benefits, but every finding behind it is rodent data from its own developers, and no human trial of Dihexa itself has ever been run. The compound that actually reached human Alzheimer’s trials, fosgonimeton, is chemically distinct and should not be assumed to share Dihexa’s safety or efficacy profile.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Cognitive support, general | Subcutaneous or oral | 5 to 10 mg per dose | Once daily | Often cycled, weeks |
Circulating cognitive-support material for Dihexa describes milligram-range oral or subcutaneous doses. There is no human trial of any kind to check that figure against. The rodent research this compound is based on describes it as engineered for extremely high potency at oral doses far below typical peptide drug quantities, without publishing a figure that scales cleanly to a milligram human dose; the circulating figure is not derived from, or comparable to, anything published for this compound.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. J Alzheimers Dis 2015;45(4):985-1000. Review by Dihexa's developers; rodent and mechanism data only. PMID 25649658
- Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol 2015;125:26-46. Review by Dihexa's developers; rodent and mechanism data only, no human trial reported. PMID 25455861
Compare Dihexa with related compounds
Research area: Neuro and cognitive.